Insilico's rentosertib shows early aging signal in IPF trial

The September 7 study in Nature Biotechnology builds on the underlying Phase II-style trial that ran in China from July 2023 to June 2024. That trial's results, published in Nature Medicine in June 2025, provided the medical anchor — a concrete measure of lung function improvement. The new aging analysis adds a second, more speculative layer: using blood samples from 42 of those participants, six aging clocks estimated younger predicted profiles, but with uneven statistical support.

This research is notable because it connects an AI-discovered target and AI-designed molecule to human testing. The identification of TNIK as the target and the molecule designed to inhibit it offer a clear link between AI drug discovery and patient outcomes, something often missing in early AI hype. However, the authors themselves note that a protein associated with fibrosis, LTBP2, influences all six clocks, meaning the apparent aging signal could partly reflect the disease itself rather than a genuine aging effect.

The stakes are practical. For people with IPF, the question is whether rentosertib can deliver a durable, tolerable benefit. Sixteen patients discontinued treatment, and the trial was short and conducted in one country. The broader point is that AI-designed drugs still face the same evaluation hurdles as traditional candidates. A 2024 analysis found roughly 40% success in phase II for AI-native biotech pipelines, similar to historical averages. Whether this early signal translates into meaningful patient benefit will depend on larger, longer studies that can validate both efficacy and safety — the real test for AI's contribution to medicine.